Distribution and Clustering of Cutaneous T-Cell Lymphoma (CTCL) Cases in Canada During 1992 to 2010

2017 ◽  
Vol 22 (2) ◽  
pp. 154-165 ◽  
Author(s):  
Feras M. Ghazawi ◽  
Elena Netchiporouk ◽  
Elham Rahme ◽  
Matthew Tsang ◽  
Linda Moreau ◽  
...  

Background: Clustering of patients with cutaneous T-cell lymphoma (CTCL) was reported in several jurisdictions around the world. This rare cancer is known to affect spouses and in some cases multiple members of the same family. These combined results suggest the existence of external disease triggers/promoters. We recently conducted the first comprehensive analysis of CTCL incidence and mortality in Canada, which revealed case clustering in several regions. Objectives: To extend our previous analysis on CTCL incidence across Canada and to provide all the collected data on CTCL patient incidence in Canada during the period of 1992 to 2010. Methods: Clinical parameters for patients with CTCL in Canada were analyzed using 2 independent population-based cancer registries: Canadian Cancer Registry and Le Registre Québécois du Cancer. The CTCL incidence rates were examined on different geographical levels, including provinces/territories, cities, and forward sortation areas. Results: Our findings further corroborate our earlier observations of higher CTCL incidence in Newfoundland and Labrador, maritime provinces (Nova Scotia and New Brunswick), and prairie provinces (Manitoba and Saskatchewan). Also, most cities with high CTCL incidence were located in these provinces. Extensive mapping of high-incidence postal codes supports case clustering in a number of communities that are located in the proximity of industrial centres and seaports. Conclusions: Detailed analysis of CTCL incidence in Canada is critical to fully understand the burden of this disease in our country, to begin the search for a possible external trigger for this lymphoma, and to reform how health care resources are distributed throughout the country to better serve Canadian patients with CTCL.

2015 ◽  
Vol 4 (9) ◽  
pp. 1440-1447 ◽  
Author(s):  
Ivan V. Litvinov ◽  
Michael T. Tetzlaff ◽  
Elham Rahme ◽  
Michelle A. Jennings ◽  
David R. Risser ◽  
...  

Cancer ◽  
2015 ◽  
Vol 121 (12) ◽  
pp. 1993-2003 ◽  
Author(s):  
Ivan V. Litvinov ◽  
Michael T. Tetzlaff ◽  
Elham Rahme ◽  
Youssef Habel ◽  
David R. Risser ◽  
...  

Cancer ◽  
2017 ◽  
Vol 123 (18) ◽  
pp. 3550-3567 ◽  
Author(s):  
Feras M. Ghazawi ◽  
Elena Netchiporouk ◽  
Elham Rahme ◽  
Matthew Tsang ◽  
Linda Moreau ◽  
...  

2018 ◽  
Vol 66 (4) ◽  
pp. 762-767 ◽  
Author(s):  
Jianhong Wang ◽  
Rong Liang ◽  
Caixia Hao ◽  
Xiangxiang Liu ◽  
Na Zhang ◽  
...  

This study aimed to investigate clinical characteristics and survival outcomes of primary cutaneous T-cell lymphoma (CTCL) in HIV-infected and non-HIV-infected patients. All data were from the Surveillance, Epidemiology, and End Results program, 1973–2013, of the U.S. National Cancer Institute. Data of 318 HIV-infected patients and 1272 non-HIV-infected patients with primary CTCL were analyzed. Endpoints were overall survival and cancer-specific mortality. Independent variables included demographics, pre-existing malignancy, treatments, and environmental factors. Among 8823 patients with CTCL, 318 (3.60 per cent) were HIV-infected and 8505 (96.40 per cent) were not. 318 HIV-infected patients and 1272 non-HIV-infected patients selected by matching diagnosis dates were analyzed, including 941 (59.2 per cent) males and 649 (40.8 per cent) females with mean age 58.8 years. HIV-infected patients with CTCL had higher survival and significantly lower risk of overall mortality than non-HIV-infected patients (adjusted HR 0.37, 95 per cent CI 0.24 to 0.59, P<0.001). Non-HIV-infected, age and black race were significant risk factors for overall mortality. Age and race are independent risk factors for overall mortality in primary CTCL individuals, and HIV-infected status is an independent protective factor, suggesting that advanced antiretroviral therapy restores immunity and prolongs survival in HIV-infected patients with CTCL.


Sign in / Sign up

Export Citation Format

Share Document